Joanna Entwistle
Principal Consultant, GFK Market Access, UK
How do we avoid the greatest threat to carefully crafted medical strategy – the inevitable boiling down of delicately nuanced arguments into bullet points, charts and tables? To the outside observer it appears to be largely generic and is hardly reassuring to senior stakeholders who must bless it, or clear to those who must ultimately implement it. This presentation will discuss how to create and communicate your medical strategy in a way that informs and inspires the reader.
Robert Barker
CEO, Succinct Medical Communications, UK
Tiberio Catania
Commercial Director
EPG Health Media, UK
Sanjay Singhvi
Director, System Analytic, UK
Chris Gray
President & Managing Director, Adelphi Communications, UK
Anne Marriott
Deputy Managing Director,
Adelphi Communications, UK
Filip Rozewski
International Business Development
MediNeos Observational Research, Poland
Bettina Rillmann
Associate Director, Scientific Affairs
PRA Health Sciences, Germany
Xavier Fournie
Corporate Medical Director, Executive Vice-President, Global Medical Affairs – Real World Evidence, MAPI, France
Alexandra Adams
Director, Late Phase, Europe
Chiltern, UK
Research questions around real-world evidence development can include a breadth of evidence needs including the prevalence, clinical characteristics, treatment patterns and effect, etc. of a given cohort and/or sub-cohort. Addressing the question(s) can be complicated by the size/characteristics of the cohort and the complexities of the health system. Consequently, we propose a practical and feasible approach to assessing study design options which we believe will meet both the research objectives as well as consider the realities of timelines and budget constraints. We will discuss a number of options for study design and cohort identification, including use of administrative claims and/or electronic healthcare records, sitebased recruitment, and web-survey panelists. We will identify a set of common methodological challenges and discuss the relative strengths of each approach in addressing these issues.
Teresa K Wilcox
Scientific Director, Real World Evidence, Evidera, USA